A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 239-243

  Uwagawa, T ^a   Misawa, T ^a   Sakamoto, T ^a   Ito, R ^a   Gocho, T ^a   Shiba, H ^a   Wakiyama, S ^a   Hirohara, S ^a   Sadaoka, S ^a   Yanaga, K ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoresistance; Gemcitabine; Nafamostat mesilate; NF B; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; MORPHINE SULFATE; NAFAMSTAT MESILATE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG STRUCTURE; FEMALE; FEVER; HUMAN; HYPERCALCEMIA; INOPERABLE CANCER; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PAIN ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GUANIDINES; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR STRUCTURE; PANCREATIC NEOPLASMS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 60549117340     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn640     Document Type: Article

References (29)

1. Sebens S, Arlt A, Schäfer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res 2008; 177: 151-164.
2. Fujioka S, Sclabas GM, Schmidt C et al. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003; 22: 1365-1370.
3. Sclabas GM, Fujioka S, Schmidt C et al. NF-kappaB in pancreatic cancer. Int J Gastrointest Cancer 2003; 33: 15-26.
4. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-888.
5. Arlt A, Schäfer H. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002; 40: 336-347.
6. Hering J, Garrean S, Dekoj TR et al. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann Surg Oncol 2007; 14: 3620-3628.
7. Uwagawa T, Li Z, Chang Z et al. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer 2007; 109: 2142-2153.
8. Tsukagoshi S. Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant: The pharmacodynamics and pharmacological action. Gan To Kagaku Ryoho 2001; 28: 1237-1243. (in Japanese).
9. Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP 2007; 8: 488-494.
10. Mikami Y, Takeda K, Matsuda K et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas 2005; 30: 248-253.
11. Kakugawa Y, Takeda K, Sunamura M et al. Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction. Nippon Shokakibyo Gakkai Zasshi 1990; 87: 1444-1450. (in Japanese).
12. Simon R, Freidlin B, Rubinstein L et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138-1147.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
15. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
16. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: From clone to clinic. Curr Mol Med 2007; 7: 619-637.
17. Weldon CB, Burow ME, Rolfe KW et al. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 2001; 130: 143-150.
18. Camp ER, Li J, Minnich DJ et al. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199: 249-258.
19. Banerjee S, Zhang Y, Ali S et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064-9072.
20. Richardson PG, Anderson KC. Bortezomib: A novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003; 1: 596-600.
21. Bernardeschi P, Dentico P, Rossi S et al. Chemoresistant myeloma: Phase II clinical study with low-dose thalidomide plus high-dose dexamethasone. J Chemother 2004; 5: 90-93.
22. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007; 34: 347-353.
23. Reni M, Cereda S, Galli L. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: The ghost regimen. Cancer Lett 2007; 256: 25-28.
24. Kindler HL. Pancreatic cancer: An update. Curr Oncol Rep 2007; 9: 170-176.
25. Vergnolle N, Bunnett NW, Sharkey KA et al. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med 2001; 7: 821-826.
26. Cottrell GS, Amadesi S, Schmidlin F, Bunnett N. Protease-activated receptor 2: Activation, signalling and function. Biochem Soc Trans 2003; 31: 1191-1197.
27. Hoogerwerf WA, Zou L, Shenoy M et al. The proteinase-activated receptor 2 is involved in nociception. J Neurosci 2001; 21: 9036-9042.
28. Maeda K, Hirota M, Kimura Y et al. Proinflammatory role of trypsin and protease-activated receptor-2 in a rat model of acute pancreatitis. Pancreas 2005; 31: 54-62.
29. Takeda K, Matsuno S, Ogawa M et al. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: Results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg 2001; 8: 216-220.